Hereditary Angioedema Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Hereditary Angioedema remains an active clinical development field. One-time and precision therapies are raising the efficacy ceiling, but durability, manufacturing, small-population evidence and long-term safety remain decisive constraints. The PatSnap evidence set used here contains 53 matched trial records and 267 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| CTR20262411 | Recombinant human C1 esterase inhibitor (Chengdu Institute of Biological Products) | Phase 2; 进行中 （尚未招募） | Beijing Joinn Biologics Co., Ltd.; Chengdu Institute of Biological Products | China | (首次 HAE 急性发作经给药后 24h 内症状开始缓解的时间。) | Timing not listed |
| NCT07654829 | Sebetralstat | Phase 4; Not yet recruiting | KalVista Pharmaceuticals Ltd. | Geography not listed | The number and proportion of STPs that did not result in an HAE attack within 24 hours after the start of the procedure will be summarized. (24 hours following the start of the procedure) | 2027-11-29 |
| NCT07559630 | Intervention not normalized | Not Applicable; Recruiting | University of California, Los Angeles | United States | Number of procedures to control bleeding (6 months) | 2030-11-01 |
| NCT07448181 | Intervention not normalized | Not Applicable; Recruiting | Istituti Clinici Scientifici Maugeri SpA | Italy | Emotional Burden via Ecological Momentary Assessment (EMA) (Every other day for 8 weeks); Socio-occupational Impairment via Ecological Momentary Assessment (EMA) (Every other day for 8 weeks) | 2027-02-28 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trials (Phase 2/3): the indexed record reports AE = Sebetralstat had a safety profile comparable to placebo.; AE = Sebetralstat had a safety profile comparable to placebo.; AE = Sebetralstat had a safety profile comparable to placebo..
- Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema (Phase 3): the indexed record reports Monthly attack rate = 2.1 Event/month ( 1.55 - 2.86); Monthly attack rate = 0.26 Event/month ( 0.15 - 0.45).
- An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema (Phase 3): the indexed record reports -; Number of Participants With Treatment-emergent Adverse Events (TEAE) = 146 Participants; -.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Recombinant human C1 esterase inhibitor (Chengdu Institute of Biological Products) (Phase 2; C1-INH), Sebetralstat (Approved; KLKB1). Company & Deal Intelligence records identify sponsor context for Beijing Joinn Biologics Co., Ltd., Chengdu Institute of Biological Products, KalVista Pharmaceuticals Ltd., University of California, Los Angeles, Istituti Clinici Scientifici Maugeri SpA. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Natural-history-aligned endpoints that remain interpretable in small heterogeneous cohorts.
- Long-term registries for durability, immunogenicity and delayed safety signals.
- Redosing, rescue and treatment-sequencing strategies after incomplete response.
- Access models that address diagnosis, manufacturing and global delivery.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Hereditary Angioedema has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
